Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer

Asian Journal of Andrology

Volumn 13, Issue 3, 2011, Pages 366-368

  Sartor, Oliver ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone; immunotherapy; metastasis; prostate cancer; radiopharmaceuticals; radium; samarium; stroma; strontium; XL 184

Indexed keywords

DOCETAXEL; DOXORUBICIN; PROVENGE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; SAMARIUM 153; STRONTIUM 89; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; DRUG POTENTIATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOTHERAPY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MALE; NEOPLASTIC STEM CELLS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIUM; STROMAL CELLS;

EID: 79955670887     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.23     Document Type: Article

References (24)

1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
2. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 008321: 1801-6.
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ et al. An integratedgenomicanalysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
4. http://www.hhmi.org/news/vogelstein20080904.html (accessed 1 November 2010).
5. Gerlinger M, Swanton C. How Darwinian modelsinformtherapeuticfailureinitiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103: 1139-43.
6. Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostatecancer. Expert Rev Endocrinol Metab 2009; 4: 417-22.
7. Guo Z, Yang X, Sun F, Jiang R, Linn DEet al. Anovelandrogenreceptorsplicevariant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-13.
8. Taylor RA, Toivanen R, Risbridger GP. Stem cells in prostatecancer: treatingthe root of the problem. Endocr Relat Cancer 2010; 17: R273-85.
9. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
10. Guzmán-Ram?́rez N, Völler M, Wetterwald A. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009; 69: 1683-93.
11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEngl J Med 2004; 351: 1502-12. (Pubitemid 39315317)
12. Laugier A. The first century of radiotherapyin France. Bull Acad Natl Med 1996; 180: 143-60.
13. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005; 23: 8232-41. (Pubitemid 46211560)
14. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ et al. Quadramet424Sm10/11 Study Group. Samarium-153-Lexidronamcomplexfortreatment of painful bonemetastases in hormone-refractory prostatecancer. Urology 2004; 63: 940-5.
15. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 336-41. (Pubitemid 32128538)
16. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S et al. Phase I studyof samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009; 27: 2436-42.
17. + cells. Radiat Res 2007; 167: 541-50. (Pubitemid 351292961)
18. Kaplan ID, Valdagni R, Cox RS, Bagshaw MA. Reduction of spinal metastases after preemptive irradiation in prostatic cancer. Int J Rad Onc Biol Phys 1990; 18: 1019-25. (Pubitemid 20182333)
19. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94. (Pubitemid 46995621)
20. deVita VT Jr, Hubbard SM, Longo DL. Treatment Of Hodgkin's disease. J Natl Cancer Inst Monogr 1990; 10: 19-28.
21. Kamrava M, Bernstein MB, Camphausen K, Hodge JW. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mol Biosyst 2009; 5: 1262-70.
22. Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009; 11: 37-42.
23. Demaria S, Bhardwaj N, Mc Bride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655-66. (Pubitemid 41400049)
24. Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, Gordon MR et al. Phase 2 studyof XL184 inacohortof patientswithcastration resistantprostatecancer (CRPC) and measurable soft tissuedisease. EJC Suppl 2011; 8: 129.